跳至主要内容
临床试验/CTRI/2022/09/046041
CTRI/2022/09/046041招募中未知

A Registry To Collect Characteristics And Outcomes From Patients With Solid Tumors Profiled With A Next-Generation Sequencing Test. - (WAYFIND-R)

F HoffmannLa Roche Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patient is currently diagnosed with any type of solid tumor cancer, at any stage of the
  • disease, at the enrolment date (informed consent date)
  • - Patient has undergone NGS testing, no longer than 3 months prior to the enrolment date,
  • irrespective of the availability of test results
  • - Informed consent has been obtained from the patient or legally authorized representative,
  • as per local regulations

排除标准

  • Patient has a prior (Disease free less than 5 years) or current diagnosis of hematological malignancy.

研究者

发起方
F HoffmannLa Roche Ltd

相似试验